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Abstract
Clinically compliant human embryonic stem cells (hESCs) should be developed in adherence to ethical standards, without
risk of contamination by adventitious agents. Here we developed for the first time animal-component free and good
manufacturing practice (GMP)-compliant hESCs. After vendor and raw material qualification, we derived xeno-free, GMP-
grade feeders from umbilical cord tissue, and utilized them within a novel, xeno-free hESC culture system. We derived and
characterized three hESC lines in adherence to regulations for embryo procurement, and good tissue, manufacturing and
laboratory practices. To minimize freezing and thawing, we continuously expanded the lines from initial outgrowths and
samples were cryopreserved as early stocks and banks. Batch release criteria included DNA-fingerprinting and HLA-typing
for identity, characterization of pluripotency-associated marker expression, proliferation, karyotyping and differentiation in-
vitro and in-vivo. These hESCs may be valuable for regenerative therapy. The ethical, scientific and regulatory methodology
presented here may serve for development of additional clinical-grade hESCs.
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Introduction
Human ESC lines [1],[2] holds promise for disease modeling,
basic scientific research, drug development, toxicity studies, and
may serve as an unlimited renewable source of cells for
transplantation therapy.
Most of the reported hESC lines worldwide are not ideal for use
in clinical trials. They were developed without adherence to Good
Manufacture Practices (GMPs), using animal-derived research-
grade reagents, which may infect the cells with animal pathogens.
Moreover, many cell lines were derived and cultured on animal
feeder cells, which may contaminate the hESCs by nonhuman
sialic acid Neu5Gc molecules, which can elicit immune rejection
after transplantation [3] and may render them as xenotransplan-
tation products [4],[5]. In order to use hESC derivatives for
clinical applications, the hESCs (clinical-grade hESCs) should
ideally be developed under stringent ethical guidelines, from
traceable and tested donors, preferably in an animal-free, GMP-
grade culture system. The hESCs should meet safety criteria
including a normal karyotype, definitive identity profile, sterility
and the absence of adventitious viruses [6],[5].
Modifications and improvements of specific components of the
hESC culture systems, which may enable their use for developing
clinical-grade hESCs have been reported. To avoid immunosur-
gery, which utilizes animal reagents, ICMs were isolated from
blastocysts by mechanical [7],[4],[8],[9] or laser-assisted-dissection
[10]. Alternatively, whole blastocysts were plated and the
pluripotent stem cells were isolated from the outgrowth
[11],[10]. The use of mouse embryonic fibroblast feeders was
replaced by human fibroblasts [12],[13],[14],[15], feeders derived
from hESCs [15], outgrowths of embryoid bodies [16], or by the
development of feeder-free defined culture systems
[17],[18],[19],[20]. To further avoid xenogenic components in
the culture system, fetal calf serum was replaced by human serum
[15] or xeno-free serum replacement [21],[22]. Recombinant [22]
or synthetic [23] extracellular matrices (ECMs), growth factors
[24] and enzymes for passaging were introduced [25],[26]. A
single group successfully developed hESC lines under xeno-free
conditions. However, although GMP-grade materials were utilized
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[27].
In order to utilize stem cells for cell therapy, they preferably
should be developed under strict cleanroom conditions, utilizing
GMP-grade reagents and compulsory documentation [5]. So far,
only a single group [24] fully complied with these requirements
and derived hESC lines under GMP conditions; however, animal
products were used in the feeder culture medium as well as the
hESC culture system.
Here we report for the first time the derivation of clinical-grade
hESC lines developed in an animal-free and GMP-compliant
culture system under cleanroom conditions. Donor eligibility was
carefully screened, in adherence to regulatory guidelines. All
aspects of donor tissue and embryo handling, hESC derivation,
culturing, cryopreservation, banking and characterization, were
strictly monitored for quality practices, in line with their future use
in transplantation therapy. The data, protocols and documenta-
tion presented here may serve as a platform for the development of
additional clinical-grade hESCs.
Results
Qualification of Materials
The study was initiated by the establishment of a quality
assurance program to identify materials which would be both
xeno-free and GMP-grade. Xeno-free candidate materials were
tested in our feeder and hESC culture systems for their
effectiveness in replacing research-grade reagents. The vendors
of effective xeno-free materials underwent a QA certification
process to ensure compliance with GMPs. To further confirm the
vendors’ quality statements we arbitrarily sampled some of the
materials for sterility, mycoplasma and LAL testing. At the
completion of this certification process, all animal-free materials
that were accepted were also GMP-grade, except for FGF2 which
was available only as a GMP-like product (Table S1).
Clinical-grade Human Feeders
To avoid the use of feeders from mouse origin, we developed
and compared feeders from three primary human tissues including
foreskin, aborted fetuses and umbilical cord. All donated tissues
were obtained subject to informed consent and Institutional
Helsinki Committee approval. Foreskin was obtained during
surgical circumcision, tissues from aborted fetuses were collected
from first trimester terminations of pregnancy and umbilical cord
was harvested during elective cesarean sections. All tissues were
obtained under sterile conditions from surgical procedures
performed in an operating room. This enabled us to avoid the
use of antibiotics in the feeder culture system, as advised by the
FDA [28], to prevent potential allergic reaction from trace
antibiotic remnants in future transplanted hESC-derived progeny.
Fibroblast feeder lines were derived from the three primary tissues
with a culture system containing humanized or recombinant, GMP-
grade reagents. After qualifying the derivation process with all
ancillary materials [29] by developing feeder lines from the three
sources under research conditions, clinical-grade lines were devel-
oped in Hadassah’s GMP Facility, in accordance with FDA Aseptic
Processing Guidelines [30] and European Agency for the Evaluation
of Medicinal product (EMEA [31]) guidelines. Three GMP-grade
umbilical cord, two foreskin, and one fetal fibroblast master cell
banks (MCBs) were derived. Short tandem repeat (STR) DNA
fingerprinting provided a unique identification profile for each line.
We characterized and compared the properties of the feeders
derived from the three primary tissues between passages 5–10 in a
GMP-compliant QC testing laboratory. Feeders from the three
sources showed typical fibroblast morphology and were immuno-
stained for vimentin, which is expressed by fibroblasts (Figure 1A).
FACS analysis showed that the majority (.80%) of the cells were
immunoreactive with anti-CD44 and anti-human fibroblast anti-
bodies (Figure 1B). The fibroblast average doubling times were
26.163.8 hours (umbilical cord), 29.969.8 hours (foreskin) and
27.263.7hours(human fetal fibroblasts; n=3:Figure 1C). All three
feeder types exhibited normal karyotypes when a minimum of 30
metaphase spreads were analyzed at passages 7–10 (Figure 1D).
To test and compare the potential of the feeders to support the
propagation of pluripotent stem cells, hESCs were cultured on the
three types of feeders pretreated with Mitomycin C. The
phenotype and differentiation potential of the hESCs was
characterized after 1–5 passages, and to ascertain the long-term
potential of the feeders to support undifferentiated propagation
also again after 6–10 passages. On the three types of feeders, the
characteristics of hESCs were similar at the early and late analysis
time points. The cultured hESCs retained the morphology of
undifferentiated cells and expressed alkaline phosphatase (AP) and
Oct-4 (Figure 2A). FACS analysis showed a comparable high
percentage (.80%) of cells expressing SSEA-4, TRA-1-60, and
TRA-1-81, while a minute percentage expressing SSEA-1
(Figure 2B). The normal karyotype of the hESCs was ascertained
by G-banding before and after their passaging on the feeders. The
doubling time of hESCs on the three types of feeders did not differ
significantly (Figure 2C).
The hESCs could differentiate in vitro within embryoid bodies
and neural spheres into progeny representing the three embryonic
germ layers (Figure 2A). Thus, the potential of the feeders from the
three sources to support undifferentiated propagation of hESCs
was similar. The full characterization of GMP-grade feeder lines is
summarized in Table S2.
We elected to use the cord as the source of feeders since it was
not associated with ethical issues such as those related to fetal tissue
donation, and was sterile, unlike disinfected foreskin. Samples of
the MCB frozen at passage level 3 of the cord feeder line CRD008
were sent to an FDA-approved laboratory for safety testing
according to FDA, EMEA, and International Conference on
Harmonisation (ICH) [32] guidelines. The cells were found to be
free of bacteria, fungi, yeasts, mycoplasmas, and adventitious
viruses. Isoenzyme analysis confirmed that the feeders were from a
human source. Karyotype analysis was normal (46XY), and
endotoxin results (LAL) were within an acceptable range [33];
Table S3).
Four samples of the MCB were expanded and frozen after c-
irradiation at passages 7–8 as four working cell banks (WCBs). The
lack of proliferating cells within thawed samples of the WCBs was
confirmed by KI-67 immunostaining and analysis of BrdU
incorporation (Figure 1E). The WCBs underwent characterization
(Table S4) similar to the MCB and limited safety testing (Table
S3). The derivation of three cord feeder MCBs and four WCBs
enabled us to meet regulatory requirements for three runs of
process validation under aseptic cleanroom conditions.
In conclusion, we developed for the first time xeno-free, GMP-
compliant and safety-tested clinical-grade human feeders from
cord tissue.
Clinical-grade hESC Culture System
Towards further developing a xeno-free, GMP-grade hESC
culture system, while utilizing the irradiated cord feeders, we
replaced porcine-skin-derived research-grade gelatin with recom-
binant gelatin. It did not adversely affect the undifferentiated
propagation of the hESCs in research grade KO medium. After 4
passages, qualitative analysis of the morphology of colonies, Oct-4
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e35325Figure 1. Characterization of human feeders. Human feeders derived from three types of human tissues showed similar properties. They were
immunoreactive with anti-vimentin (A; immunostaining, nuclei counterstained with 4’, 6-diamidino-2-phenylindole (DAPI)), CD44 and human
Fibroblast antigens (B; FACS analysis). They had similar doubling times (C) and normal karyotypes (D). c-irradiated cord feeders (WCB2) were
mitotically inactive as indicated by lack of KI-67 expression and BrdU incorporation (E; immunostaining (green), nuclei counterstained with DAPI
(blue)). Mitomycin-C treated and mitotically-active non-treated feeders served as negative and positive controls, respectively. (B & C present analysis
of three lines from each feeder type).
doi:10.1371/journal.pone.0035325.g001
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analysis of the percentage of cells expressing markers of
pluripotency was similar with both gelatins (Figure 2E). In the
next step, we identified a commercially available serum-free stem
cell growth medium (SCGM; CellGroH/CellGenix
TM) which is
designed for the expansion of hematopoietic and natural killer
cells. SCGM is produced under GMP, is animal-free and is
intended for clinical ex vivo cell culture use.
We compared the potential of SCGM (supplemented with
FGF2) with KO medium to support undifferentiated propaga-
tion of hESCs on cord feeders and recombinant gelatin. After 4
passages, the morphology of colonies was similar and the stem
cells expressed Oct-4 and AP (Figure 2D). The percentage of
cells expressing TRA-1-60 and TRA-1-81 was 75.664.9% and
7464.9%, respectively, with SCGM, significantly (P,0.01)
lower compared to KO Medium. Upon supplementation of
Figure 2. The development of a clinical-grade hESCs culture system. Feeders derived from the three types of human tissues were equally
effective in maintaining undifferentiated pluripotent growth of hESCs (HES-1[2]) for a minimum of 5 passages within research-grade KO medium. (A)
The hESCs cultured on the three types of feeders formed colonies with typical morphology (phase contrast images), expressed alkaline phosphatase
(AP), and were immunoreactive with anti-Oct-4 (nuclei were counterstained with DAPI). They were pluripotent as demonstrated by their potential to
differentiate in-vitro into progeny representing the three germ lineages. Immunofluorescence staining showed differentiated cells expressing beta-
tubulin III (ectoderm), muscle actin (mesoderm) and alpha-Feto-Protein (AFP, endoderm). (B) FACS analysis showing that the percentage of cells
expressing markers of pluripotent human stem cells, and the level of background differentiation (percentage of SSEA-1 expressing cells) was similar
(n=3). (C) The hESC doubling time did not differ significantly after culture on the three types of feeders (n=3). Cord feeders were further used for the
development of the clinical grade culture system, and the phenotype of hESCs was compared after culture within research-grade KO medium system
and following replacement and supplementation with xeno-free and GMP-grade reagents. The following culture compositions were compared:
hESCs cultured on porcine gelatin (porc-gel) or in recombinant gelatin (rec-gel) in KO medium, SCGM and SCGM supplemented with HSA (SCGM-
HSA). (D) With all culture conditions, the hESCs colonies had similar and typical morphological characteristics (phase contrast images), and the stem
cells expressed alkaline phosphatase activity (red) and Oct-4 (green; blue-DAPI nuclear counterstaining; immunofluorescence images). (E) The
percentage of cells expressing Tra-1-60 and Tra-1-81 was analyzed by FACS and compared between the various culture conditions (n=4). Scale bar in
(D) represents 200 um.
doi:10.1371/journal.pone.0035325.g002
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of undifferentiated cells improved to 81.462.7% and 8361%,
respectively. These percentages were slightly lower but not
significantly different in comparison to KO medium (Figure 2E).
The doubling time of hESCs was similar in SCGM supple-
mented with FGF2 and HSA compared to the KO-based
culture system (23.7562.5 (n=6)), compared to 23.3061.8
(n=8), respectively).
We next analyzed the feasibility of cryopreservation of hESC
clusters by both slow cooling and vitrification methods using
animal-free GMP-grade reagents. Slow cooling was performed
either within human serum supplemented with 10% DMSO or a
commercially available FDA-approved cryo-solution medium
(CryoStorH). Ten clusters of hESCs were cryopreserved per vial.
With both solutions, undifferentiated hESCs could be retrieved
and propagated after thawing from each tested vial (n=5 vials per
solution). The percentage of cryopreserved hESC clusters that
survived and gave rise to undifferentiated colonies upon plating
was similar with human serum-DMSO and Cryostore solutions
(31.464.34% and 32.664.52%, respectively). For practical
reasons CryoStorH solution was further used for cryopreservation
of hESCs.
Vitrification was conducted using commercially available
solutions, which are FDA-approved for cryopreservation of
embryos. Sealed straws (FDA-approved and CE marked) were
utilized to avoid potential contamination from liquid nitrogen.
Similar to slow cooling, undifferentiated hESCs could be retrieved
and propagated from each thawed straw (5 vitrified clusters/straw;
n=6 straws). The percentage of surviving clusters that gave rise to
undifferentiated colonies was 4767.4%. These results showed that
both slow cooling and vitrification methods that utilize xeno-free
GMP-grade reagents allowed reliable retrieval of cryopreserved
hESCs.
Thus we validated that the newly developed culture system
could support the undifferentiated propagation and cryopreserva-
tion of hESCs and was ready for use under GMP conditions for
the derivation of clinical-grade lines.
Ethics of hESC Development
The study was approved by the Hadassah Medical Center IRB
and the Israeli Ministry of Health’s National Ethics Committee for
Genetic Research in Humans. Supernumerary IVF embryos not
intended to be used for fertility purposes and which were
cryopreserved for at least five years were eligible for recruitment
to the study. This was in line with Israeli IVF regulations, which
permit, subject to the couples’ consent, the discarding or donating
to research of embryos frozen for five years. In order to ensure free
informed consent, the team of physicians which treated the donors
as IVF patients and obtained their consent was not the same team
which was involved in the development of the hESC lines. In order
to maintain strict confidentiality of the donors, they received a
unique identifying code and all documents relating to them and
hESCs produced from their embryos were labeled with it. Given
that the derived hESCs were intended for clinical use, blood
samples from the donors were archived, and a route was
established to obtain in the future, if needed, subject to donor
permission, additional medical information or blood tests.
Approach of the donors for this purpose would only be possible
after obtaining approval by the Hadassah Director of the
Department of Gynecology. Donors were advised that they would
not receive any information about the hESC lines, compensation
or benefit for their donation, and would not influence or have any
involvement in the use of the hESC lines.
Recruitment, Screening and Monitoring of Embryo
Donors
Potential donor couples who met the ethical eligibility criteria
mentioned above received information about the study and their
questions were answered. Those interested signed informed
consent documents (Attachment 1, File S22) including an
authorization to review their medical histories (File S25). The
donors were screened according to the FDA’s Donor Eligibility
Regulations for Human Tissues and Cells [34], including: (a) a
physical examination; (b) review of donors’ medical records to
rule out disqualifying medical conditions; (c) an interview/screen
for lifestyle risk factors; and (d) serum and swab samples, which
were sent for testing using FDA-approved test kits. Results of
these tests (Table S5) were sent to the donors. Screening
through interview was performed where no acceptable test kit
existed, such as for vCJD, sepsis, West Nile, and Vaccinia
viruses. All the information related to donor screening and the
status and quality of the donated embryos were recorded in the
donors’ Case Report Form (CRF). The CRFs and study forms
used in the hESC trial are given in Table S6, and Files S2, S3,
S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17,
S18, S19, S20, S21, S22, S23, S24, S25, S26, S27, S28, S29,
S30, S31, S32.
The trial was monitored for veracity by a clinical trial associate
(CRA). Source data which included verification of the donors’
health histories was included in the CRFs for donors whose
embryos resulted in usable hESC lines.
Donors with verified good health histories from preferred
countries of origin (low variant Creutzfeldt-Jakob disease and
malaria prevalence) and with low reported lifestyle risks were
selected to participate in the program. Exclusion criteria included
lifestyle and behavioral risks (File S28), or medications and diseases
that could have affected the quality of the embryos (Files S30,
S31).
Derivation of Clinical Grade hESC Lines
One hundred embryos were recruited from 12 couples and were
thawed in the IVF laboratory. 77 embryos survived thawing of
which 34 developed to the blastocyst stage. Details regarding the
developmental stage and morphological score of the blastocysts at
the time of ICM isolation are summarized in Table S7. To avoid
the use of animal-derived products, zona pellucida drilling and
separation of the ICMs was performed with the assistance of laser
according to our previously described protocol [10]. 23 ICMs were
successfully isolated from blastocysts that had well developed
ICMs. Eight blastocysts that either had poor ICMs or collapsed
during ICM isolation were plated whole on the human feeders.
Three blastocysts were damaged during the procedure and were
discarded (Table S7).
The isolated ICMs and whole blastocysts were transferred
from the IVF laboratory to the GMP-facility following Good
Tissue Practices (GTPs), and were plated on the irradiated cord
WCB feeders within the clinical-grade hESC culture medium.
After 5–8 days, groups of small, tightly packed cells proliferated
from the outgrowths of 7 ICMs and a single whole blastocyst.
They were mechanically dissected from the outgrowth of
differentiated cells and, following replating, gave rise to flat
colonies of cells with the morphological appearance of hESCs.
The colonies were expanded and early stocks were frozen.
Given the difficulty in the expansion of undifferentiated colonies
in five of the hESC derivations, we did not attempt to further
propagate them beyond this stage. In three derivations, which
were more easily propagated as undifferentiated colonies, the
early passage (5–9) stocks were frozen by both vitrification and
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methods for backup reasons given the limited and comparable
efficiencies of these methods under clinical-grade conditions.
These three stocks (early banks: HAD-C 100, HAD-C 102 and
HAD-C 106) underwent STR fingerprinting and HLA class I
and II antigen profiling for identity determination, sterility
testing and abbreviated characterization including, karyotyping,
and limited analysis of the expression of markers of pluripotecy
(Table S8).
The colonies of these three derivations were continuously
expanded from the initial outgrowths to avoid repeated freezing
and thawing. Samples were pooled and frozen at passages 11–24
as Primary Cell Banks (1u CB; by both cryopreservation methods;
see Figures S1 and S2) and following additional expansion,
cryopreserved (passages 16–33) as secondary CBs (2u CB by slow
cooling) (Table S8, and Figure S3). Thus we followed the
suggested two-tiered cell banking system (as described in [35])
with modifications. The derivation of three independent hESC
CBs and their characterization, as described below, enabled us to
meet regulatory requirements for three runs of process validation
under aseptic cleanroom conditions. A flow diagram showing the
steps we took in the derivation of our clinical-grade hESC lines is
shown in Figure 3.
Characterization of Clinical-grade hESCs Lines
Detailed characterization was conducted on the primary (HAD-
C100, 102 and 106) and secondary (HAD-C-100) CBs that were
frozen by slow cooling. For characterization, thawed samples of
the clinical grade hESCs were cultured in the GLP laboratory in
the same culture conditions as in the derivation process.
The hESCs colonies showed typical morphology and the
karyotype of the three lines was normal. The STR and HLA
profiles of the CBs were identical to the profiles of the early stocks,
verifying the identities of the CBs (The STR and HLA profiles are
not shown to maintain the confidential identity of the donors). The
colonies showed alkaline phosphatase activity and were immuno-
reactive with anti Oct-4, TRA-1-60 TRA-1- 81, SSEA-3 and
SSEA-4 antibodies. FACS analysis of markers for pluripotent
hESCs of the 1u CBs and 2uCB showed that the majority of cells
expressed TRA-1-60, TRA-1-81 and SSEA-3 (Figure 4 and
Figures S1, S2, S3 and Table S8).
Background differentiation was evaluated by FACS analysis of
the percentage of cells expressing SSEA-1 and was shown to be in
the range of 5–36% for all lines (Table S8). KI-67 immunostaining
showed that the majority of cells were in an active cell cycle
(.87% of the cells stained positive for KI-67, Figure S4, Table
S8). Doubling time of thawed hESCs from the 1u CBs was in the
Figure 3. Process flow diagram of the approach taken in deriving xeno-free clinical-grade fibroblast feeders and hESCs. The scheme
indicates the ethical, scientific, and regulatory steps taken in deriving our clinical-grade fibroblast feeders and hESCs.
doi:10.1371/journal.pone.0035325.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e35325Figure 4. Characterization of HAD-C 100 16 cell bank. The hESCs colonies had the typical morphology of human pluripotent stem cell colonies
with clear distinguishable borders from the cord feeder cells (A; phase-contrast image). The cells expressed alkaline phosphatase (B; AP, fluorescence
image). Indirect immunofluorescence staining showed that the hESCs were immunoreactive with anti-Oct-4 (C; nuclei counterstained with DAPI, D),
TRA-1-60 (E), TRA-1-81 (F), SSEA-3 (G), and SSEA-4 (H). FACS analysis showed that the majority of cells expressed markers of pluripotency TRA-1-60 (I),
TRA-1-81 (J) and SSEA-3 (K) (Data from a representative experiment). The hESCs had normal karyotype (46, XY; L) and could differentiate in vitro and in
vivo into cells representing the three embryonic germ layers (M-R). Immunofluorescence staining showing in vitro differentiated cells expressing beta-
tubulin III (ectoderm, M), muscle actin (mesoderm, N) and sox-17 (endoderm, O). Hematoxylin-eosin stained histological sections of teratoma tumors
showing neural rosettes (ectoderm, P), cartilage (mesoderm, Q) and villi structures with columnar glandular epithelium and goblet cells (endoderm,
R). Scale bar represent 50 um for (A, B, Q and R), 100 um for (C, D, M, N, O and P) and 200 um for (E–H).
doi:10.1371/journal.pone.0035325.g004
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from the 2uCB of HADC-100 was similar to that of the 1u CBs
(Table S8).
The pluripotent potential of the three hESCs lines was
demonstrated by their capability to differentiate into progeny
representing the three embryonic germ layers in-vitro and in-vivo.
Following 3–4 weeks of differentiation as embryoid bodies (EBs),
immunofluorescence staining showed cells expressing beta-tubulin
III (neuronal marker, ectoderm), muscle actin (mesoderm) and
sox-17 (endoderm; Figure 4M-O and Figures S1, S2, S3M–O).
When clusters of hESCs from the three lines were inoculated
subcutaneously into SCID mice, teratoma tumors developed and
were analyzed histologically after 8–12 weeks. Hematoxylin-eosin
stained sections showed neural rosettes (ectoderm), cartilage
(mesoderm) and columnar glandular epithelium with goblet cells
(endoderm; Figure 4P–R and Figures S1, S2, S3P–R).
Safety testing for adventitious viruses of the hESC lines was
negative and is shown in Table S9.
Gene expression analysis. RNA was prepared from undif-
ferentiated hESCs colonies and EBs from each one of the lines.
Gene expression was analyzed by the same Human Stem Cell
Panel array that was previously used by the International Stem
Cell Initiative (ISCI [36]) to analyze 59 lines. Gene expression of
each gene is reported as its DeltaCt value normalized against the
average Ct of three selected endogenous control genes (18 S, beta-
actin and GAPD-H; Table S10). Using the combined data of
undifferentiated and differentiated samples, we tested the pairwise
Pearson correlation of expression of the genes to the expression of
NANOG (Figure 5A). The expression of genes that are associated
with pluripotency including GABRB3, GDF3, SOX2, POU5F1,
DNMT3B, TERT, LIN28 and TDGF1 [36] was highly (r.0.88)
correlated with the expression of NANOG. Five of these genes
(GABRB3, GDF3, POU5F1, DNMT3B and TDGF1) were also
found to be highly correlated (r.0.75) with the expression of
NANOG in the ISCI study [36]. Genes that are known to be
commonly associated with differentiation such as CDX2, GATA6,
AFP, CD34, PECAM1, TH and ISL1 showed negative correlation
(r,20.75) with NANOG expression.
Weperformedtwo-wayhierarchicalclusteringanalysisofthethree
clinicalgradehESClineswithrespecttogeneexpression.Thegenes
thatarepresentedinFigure5Barethosethatsignificantlydifferedin
theirexpressionbetweenundifferentiatedanddifferentiatedsamples
(unpairedt-test;P,0.05).Clusteringresultsshowtwodistinctsample
clusters: one includes the undifferentiated cells ofthe three lines and
the other the differentiated cells. The data also shows two clear
clustersofgenesexpressedbyundifferentiatedanddifferentiatedcells
in each one of the samples. The genes NANOG, GABRB3, GDF3,
POU5F1,DNMT3BandTDGF1,thatweretypicallyupregulatedin
thepluripotentstateintheISCIstudy,werealsohighlyexpressedby
the three clinical-grade undifferentiated cell line samples and were
down regulated upon differentiation. Genes that are expressed by
differentiatedcells(suchasAFP,GATA4,GATA6,FN1,COL1A1)
[36]werehighlyexpressedintheEBsinallthreelinesandweredown
regulated inthe undifferentiated hESCs.
Discussion
In this study we derived for the first time xeno-free and GMP-
grade human feeders and ESC lines adhering to regulatory
guidelines. We developed a unique animal reagent-free culture
system for the derivation of the new hESC lines as well as the
regulatory platform for donor selection and testing, which can
serve for the establishment of additional clinical-grade lines. The
hESC lines developed in this study may be utilized for the
development of differentiated cells for transplantation therapy.
The ethical considerations that guided the development of the
hESCs strictly followed Israeli law [37,38] and adopted the
recommendationsoftheBioethicsAdvisoryCommitteeoftheIsrael
National Academy of Sciences and Humanities [39]. They were in
linewiththeethicalguidelinesoftheISSCR(www.isscr.org),theUS’s
NationalAcademyofSciences(www.nasonline.org)andtheNational
Institute of Health (NIH: http://nih.gov). The three lines were
approved for inclusion in the NIH Human Embryonic Stem Cell
Registry (http://grants.nih.gov/stem_cells/registry/current.htm),
and therefore canbe utilized infederally funded researchin the US.
Theymaybeusedworldwidesubjecttospecificnationalregulations.
TheethicalconsiderationsthatguidedthederivationofhESClinesin
this report, and the draft informed consent for the recruitment of
embryo donors, may be valuable to other research groups deriving
new clinical-grade hESClines.
For the establishment of a hESC culture system that will be
compliant for future clinical use, we established a material
qualification process. We verified that the materials were primarily
of GMP-grade, and were xeno-free. Vendors’ adherence to GMP
was ascertained by questionnaire and some materials were quality
tested. Qualified materials were then introduced into the
development process of our protocols in the research environment
and tested for their suitability. The vendor quality approval,
material quality testing and reagents’ qualification in the process
guaranteed that reproducible and safe hESC lines were derived.
The derivation protocols, which incorporated these materials,
were initially used to develop, for the first time, xeno-free, GMP-
grade human feeders from three sources; umbilical cord, foreskin
and fetal tissue. We showed that the feeders from the three sources
were similarly potent in supporting the undifferentiated propaga-
tion of hESCs, and hence elected to work with umbilical cord due
to its many advantages.
Cord may be obtained during elective cesarean sections as a
completely sterile tissue compared to foreskin which can only be
disinfected before sampling. Cord blood can be easily harvested in
sufficient quantities for donor safety testing, as compared to the
ethical constraints and technical difficulties in obtaining sufficient
blood sampling from infants undergoing circumcisions. Addition-
ally, unlike with aborted fetal tissues, there is no moral debate
regarding the use of umbilical cord tissue for research purposes.
At an early stage of the project, we identified a GMP-grade
xeno-free media formulation that supported self-renewal of hESCs
at an efficiency not significantly different compared to the
standard KO research grade medium. At present, additional
GMP-grade and animal-free media designed for the propagation
of hESCs are available, though their capability to support
derivation and long term propagation of genetically stable
clinical-grade pluripotent hESC lines has yet to be demonstrated
and compared with the culture system reported here. At present,
guidelines for screening of donors of embryos that will be used for
deriving hESC for therapeutic applications have not been
established by regulatory bodies. Hence, we adopted the FDA’s
HCT/P [34] regulations for screening of organ, cell and gamete
donors as well as the EC’s blood banking and organ donation
criteria for screening of donors. Based on these criteria, we
developed a detailed series of questionnaires (CRF) of which we
here include samples for potential use by future developers of
clinical grade lines. It should be noted that it is questionable
whether the intensive interview and history-taking process have a
significant contribution to safety analysis of donated biologics.
Donors are hesitant to reveal private intimate details of past
relationships [40],[41]. We therefore complemented the question-
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reproductive tract for the absence of adventitious viruses. In
addition, a reported medical history in an interview may be
incomplete because of the donors’ partial understanding of their
medical conditions. Therefore, according to FDA guidelines, we
reviewed the medical charts of the embryo donors and confirmed
their medical histories.
We utilized a laser-based method to assist hatching and to
dissect the ICMs to avoid the use of animal derived products. The
efficiency of ICM isolation from blastocysts with well defined
ICMs was 85% (23 ICMs from 27 blastocysts) and the efficiency of
hESC line derivation was 11% (3 lines from 27 blastocysts). This
efficiency is lower than the reported derivation efficiency of hESC
lines under research-grade conditions (13%–52%) [42],[43]
including in our hands while using the laser system (30%) [10].
A low efficiency (4.75%) of hESC derivation under conditions
necessary to derive hESC lines of therapeutic grade was also
reported by others [44]. It appears that translation to xeno-free
culture system and GMP conditions is associated with a reduced
derivation success.
We established a modified banking system which included an
early stock, 1u and 2u CBs to address potential pitfalls related to
the properties of hESCs. The stocks were developed as reservoirs
of early passage cells for identity determination, and as backups for
the development of additional banks in various circumstances such
as the unfortunate loss of the hESCs to differentiation or
contamination.
Accordingtothewidely-acceptedtwo-tieredcellbankingsystem,a
mastercellbank(MCB)isinitiallyestablished,andworkingcellbanks
(WCBs) are further developed from thawed vials of MCB. hESCs
poorlysurvivecryopreservation[45]andthestressesthatareimposed
on hESCs during cryopreservation and thawing, may potentially
select for genetically abnormal cells which may survive unfavorable
culture conditions [45],[46]. Therefore, to limit the number of
freezing and thawing steps, we modified the typical two-tiered
banking approach and continuously expanded the hESCs from the
initial outgrowths until the freezing of the 2u CBs. During this
expansion, hESCs were sampled to generate early stocks and
subsequently 1u and 2u CBs. The complete records of all stocks and
banks,includingtheirorigins,detailsoftheirderivation,propagation
Figure 5. Gene expression analysis of undifferentiated and differentiated progeny of the three hESC lines. Pairwise correlation of
NANOG expression with that of all tested genes of the panel of HADC-100, HADC-102 and HADC-106 hESCs is presented in (A). Gene expression is
presented by the DeltaCt value of each gene, normalized against the average Ct of three endogenous control genes (Table S9). The Pearson
correlation coefficient was calculated from the combined data of DeltaCt values of undifferentiated and differentiated hESCs of the three lines. The
results were plotted in descending order of the correlation coefficient values. Clustering analysis of genes that were differentially expressed in the
three lines in the undifferentiated and differentiated state is presented in (B). An unpaired t-test for differential gene expression between
undifferentiated and differentiated samples yielded 35 genes with a P- value ,0.05. Two-way hierarchical clustering with Euclidean distance was
performed on the 35 genes and six samples. Green colors in the heat map represent low DeltaCt or high expression. Red colors represent high
DeltaCt or low expression.
doi:10.1371/journal.pone.0035325.g005
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histories of the lines.
Characterization of the lines was initiated by determining the
identity of each line at the early stock phase by DNA
fingerprinting and HLA analysis. It has been previously shown
that mix-ups of lines [47],[48],[49] and cross-cell contamination
[50],[51], both leading to false identities, are common occurrences
in cell banking. Therefore, the unique genetic signature deter-
mined at the stock stage of each hESC line was confirmed by STR
and HLA analysis at the 1u and 2u Cell Bank stages. The strict
determination of the lines’ identity is important for the essential
confirmation of the identity and origin of the differentiated cells
that will be developed from them for transplantation.
The specifications for the characterization of the hESC lines
were developed on the basis of ICH guidelines (Q5D) [32],
recommendations of the International Stem Cell Banking Initia-
tive [52], and regulatory experts [5]. Careful development of a
reproducible and validated derivation process, utilization of
documented protocols and qualified, verified raw materials
enabled the derivation of hESC banks that adhered to the
characterization specifications (batch release criteria).
We performed G-banded karyotype analysis to determine the
absence of chromosomal abnormalities. The International Stem
Cell Banking Initiative [52] recommends analysis of 30 metaphase
spreads for the characterization of research-grade lines. Analysis of
30 spreads was also reported for the characterization of hESC lines
derived under cleanroom conditions [24]. Fifty spreads were
analyzed in this report as it has been shown that the probability of
detecting mosaicism patterns increases when the numbers of tested
metaphase spreads increase [53]. We thus provide a higher
confidence level of the exclusion of mosaicism than previously
reported.
Internationally accepted criteria for the characterization of
hESC lines were established on the basis of the characterization of
59 hESC lines from multiple laboratories worldwide by the ISCI
study [36]. To adhere to these standards, which include gene
expression profiling, and to allow the inclusion of the new lines in
the ISCI Registry (www.stemcellforum.org), we analyzed gene
expression utilizing the same stem cell array that was used by
ISCI. The gene expression profile of the three clinical-grade hESC
lines was comparable to the profile of the research-grade lines that
were characterized in the ISCI study [36]. The genes that were
suggested by the ISCI study to be common to undifferentiated
hESCs were expressed by the pluripotent hESC of the three lines
and were downregulated upon differentiation.
The first clinical trials with hESC-derived progeny have recently
commenced, stressing the need for developing clinical-grade lines
that can be utilized to translate hESC research into the clinic. In
this paper, we present ethical, scientific and regulatory platforms
for the development of xeno-free and GMP-grade hESC lines,
which may serve the research community for the derivation of
additional clinical-grade lines. The animal-free, regulatory-com-
pliant hESC lines derived here will be valuable for developing
regenerative therapies.
Materials and Methods
Ethics Statement
The study was approved by the Hadassah Medical Center IRB
and the Israeli Ministry of Health’s National Ethics Committee for
Genetic Research in Humans (13.01.2004). A copy of our
informed consent document is included as File S1 in our
manuscript. In all cases, written informed consent was obtained
by our donors prior to their acceptance into our study, and the
clinical investigation was conducted according to the GCPs and
Helsinki guidelines.
Fibroblast Tissue Procurement
Human fibroblasts were obtained from foreskin, umbilical cord,
or fetal tissue (10–12 weeks of gestation). Potential donors were
approached only after they had decided to undergo each of the
surgical procedures (infant surgical circumcision, cesarean section,
termination of pregnancy). Tissue donors were screened for
eligibility, according to FDA’s Donor Eligibility Regulations 2004
[34]. Their medical histories were examined, blood and repro-
ductive systems (in the case of umbilical cord, and fetal tissues)
were sampled for infectious and sexually-transmitted disease
testing (Table S5), and the donors were interviewed to complete
extensive lifestyle questionnaires to minimize chances of transmis-
sion of contaminants to eventual cell recipients. Blood samples
were obtained from circumcised infant and his parents, fetal tissue
donors, the cord and both parents. They were sent for infectious
disease testing and serum was archived at Hadassah. All infectious
disease screening was performed by FDA-approved tests at
American Medical Laboratories (Herzliya, Israel).
Derivation and Cryopreservation of Human Fibroblast
Feeder Cells
Preparation of fibroblasts from umbilical cord. During
cesarean sections, after detachment of the placenta, a 10 cm
segment of cord was sampled and transferred under sterile
conditions into PBS within a prelabeled vessel, which was sealed
and transferred to the GMP facility. The cord tissues were minced
with 2 sterile surgical blades (#22) or a surgical blade and forceps.
A T75 flask (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA)
was held vertically and small pieces of tissue were transferred with
a pipette to the wall of the flask. Fibroblast Growth Medium
(FGM) comprised of DMEM, L-Glutamine 200 mM, (both from
Hyclone, Thermo Scientific, Logan, Utah), 20% Human Serum of
blood type AB (Male Only, Lonza Walkersville, MD, USA) was
then added to the bottom of the flask without disturbing the
tissues. Flasks were incubated vertically at 37uC, 5% CO2. On the
following day, the flasks were gently tilted to moisten the tissue and
remained in a vertical position. On the following day, the flasks
were placed in a horizontal position for further culture for 17–22
days until the outgrowths of cells formed a confluent monolayer.
The cells were split 1:3 twice a week using TrypLE Select
recombinant trypsin (Invitrogen, Grand Island, NY, USA). At
passage 3 or 4, when the batches contained 195–243 million cells,
master cell banks (MCB) were frozen. The fibroblasts were
removed from the flasks with TrypLE Select, resuspended in
FGM, centrifuged at 900 RPM for 4 minutes, resuspended and
pooled within FGM, and then counted by Trypan Blue exclusion
staining to confirm viability in .80% of cells. Samples from the
pool were sent to a local accredited testing lab (Hy Labs, Nes
Tziona, Israel) for sterility, mycoplasma (culture), and LAL
(Limulus Amebocyte Lysate) testing. After centrifugation as above,
the cells were frozen (2 million cells per cryovial (NUNC, Roskilde,
Denmark)) within 1 ml of 90% Human Serum AB (Lonza) and
10% DMSO (CryoSure, WAK-DMSO-10, WAK-CHEMIE
Medical GmbH, Steinbach/Ts. Germany), by a standard slow
cooling procedure, and stored in the vapor phase of liquid nitrogen
tanks (Custom Biogenic Systems V1500B, Romeo, Michigan
USA,).
Preparation of fibroblasts from foreskin. Foreskins were
obtained from infants up to one year of age from surgical
circumcisions. The foreskins were disinfected by Chlorhexidine
(dissolved in alcohol) prior to circumcision. The foreskins were
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sides of the tissues were cut with sterile scissors so that the tissues
became flat. The top layers of the inner and outer sides were
scraped with #22 surgical blades. The tissues were minced;
derivation and cryopreservation of fibroblasts MCB proceeded as
above.
Preparation of fibroblasts from fetal tissue. Tissues from
aborted human fetuses were obtained from the operating room
and transferred to the GMP-facility as above. The tissues were
mechanically minced, and 2 ml of TrypLE Select (Invitrogen)
were added for 10 minutes at 37uC. Fibroblast Growth Medium
(FGM) was added followed by pipetting and centrifugation at
1000 rpm for 3 minutes. The cells were resuspended and 4–8610
6
cells in 10 ml Fibroblast Growth Medium were seeded in a T25
flask (Falcon). The cells were incubated in 37uCa t5 %C O 2, and
when confluent, split, expanded and frozen as above.
Development of irradiated working cell banks (WCB) of
cord feeders. Vials of feeder MCB were thawed and expanded
as above up to passages 7–8 when the batches contained 350–475
million cells. The fibroblasts were pooled, and were sampled for
sterility, mycoplasma and LAL testing as above. The fibroblasts
were then irradiated within 30 ml medium (1–1.6610
6/ml) in
50 ml tubes at 3500 rads (Gammacell, 220 Exel, MDS Nordion),
repooled, recounted by Trypan Blue exclusion staining and
cryopreserved using the methods described for the MCBs.
Characterization of Feeders
Doubling time of feeders. 5610
4 fibroblasts were seeded
per well of 12-well tissue culture plates on day 0. On four
subsequent days, the number of fibroblasts in three wells was
counted, taking the average of the three. Cell counts were then
plotted versus the time of cells harvest using Microsoft Excel
software. The software was used to plot the optimized exponential
trend line and its equation. The equation was used to calculate the
time interval for population doubling.
BrdU and KI-67 staining of fibroblasts. 25,000–30,000
irradiated human fibroblasts were seeded on 0.1% gelatin-coated
coverslips, incubated for 7 days at 37uC in FGM. Mitomycin-
treated (Bedford Labs, Bedford, OH, USA) cells were cultured as
above as negative controls. For positive controls 30,000 non-
irradiated human fibroblasts were seeded and cultured for two
days.
For BrdU staining the samples were incubated with BrdU
(50 mM final concentration, Sigma, St. Louis, MO, USA) for 1
hour at 37uC and the cells were fixed with 4% PFA. The cells were
treated with HCl (1 N and 2 N) and Sodium Borate buffer
(0.1 M). The plates were incubated overnight with anti-BrdU
(1:50, Dako, Glostrup, Denmark) and the secondary antibody was
goat anti-mouse Ig conjugated FITC (1:50, Dako). For KI-67
staining cells were fixed with 0.5–1 ml 4% PFA for 20 min at RT
and incubated with anti KI-67 (1:100, Rabbit Polyclonal Antibody
KI-67 Antigen, Novo Castra Laboratories, Newcastle-upon-Tyne,
UK) for 30–60 minutes at RT. The secondary antibody used was
Polyclonal Swine Anti-Rabbit Ig conjugated to FITC (1:10, Dako).
Slides were visualized after mounting and nuclear counterstain-
ing (Vectashield, Vector Laboratories, Burlingame, Ca, which
includes 49, 6-diamidino-2-phenylindole (DAPI)) with a Nikon
E600 fluorescent microscope.
Immunostaining of feeders. 30,000 fibroblasts were seeded
onto laminin-coated coverslips and incubated in FGM for an hour,
fixed with 4% PFA for 20 min and permeabilized with Triton
X100 (0.2%, Sigma), normal goat serum (5%, Biological
Industries, Kibbutz Beit Haemek, Israel), Na Azide (0.1%, Sigma)
in PBS for 20 min. The cells were incubated for 20–30 min at RT
with anti-Vimentin (1:100, Dako) followed by incubation with
FITC-labeled goat anti-mouse Ig (1:50, Dako) and mounting as
above.
FACS analysis of fibroblasts. Fibroblasts were dissociated
using TrypLE Select (Invitrogen) followed by gentle trituration to
a single-cell suspension, centrifuged and resuspended in FACS
buffer (PBS supplemented with 0.1% Na Azide and 1% BSA). The
cells were incubated with anti-CD44-FITC (1:10, IQ Products,
Groningen, the Netherlands), anti-human fibroblasts (1:100, Acris,
San Diego, CA, USA) and with the respective isotype control
antibodies for 30 min at 4uC. Following washing, primary
antibodies were detected by incubating with FITC-labeled goat
anti-mouse Ig (1:100, Dako) for 30 min at 4uC. Following washing
the cells were resuspended in FACS buffer supplemented with PI
(1:500, Sigma 1 mg/ml). FACS analysis was performed using the
FACSCalibur system (Becton Dickinson).
Karyotyping of feeders. Fibroblasts were incubated for 40
minutes with Colcimide (100 ng/ml, Beit Haemek), washed with
PBS, dissociated with TrypLE Select (Invitrogen) for 4 minutes at
37uC, centrifuged at 1000 rpm for 5 minutes, resuspended in 1 ml
of growth medium into which 5 ml of warm KCl and Sodium
citrate hypotonic solution (Sigma) were added dropwise, incubated
for 30 min at 37uC, followed by fixation at RT with 3:1 methanol/
acetic acid for 5 min. Centrifugation and fixation of the cells were
repeated twice. The karyotype of 30 metaphases was analyzed
using the G-banding method. Full analysis was performed on 20
metaphases spreads, chromosome counting on an additional 10
spreads, and 2 cells were photographed.
STR analysis for feeders. Genomic DNA was extracted
using QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden,
Germany). STR (Short Tandem Repeats) profiles of 16 sites
(D13S317, D7S820, D16S539, vWA, TH01, TPOX, CSF1PO,
D8S1179, D21811, D19S433, D18851, D3S1358, D2S1338,
D5S818, FGA and amelogenin (for gender determination)) were
obtained using the identifier kit (PE Applied Biosystems Corona,
CA, USA).
The STR analysis was performed in the Hadassah Tissue
Typing Unit.
hESC doubling time when cultured on various
feeders. Mitomycin-treated (Bedford Labs) 10
5 MCB fibro-
blasts or irradiated WCB fibroblasts were seeded into each of 16
wells of 12-well tissue culture plates coated with gelatin. After 24–
96 hours, hESCs were seeded (20,000 hESCs per well) into 12
wells, leaving four wells as controls. At 4 time points within a week,
the cells were harvested with Trypsin-EDTA (Invitrogen), the
average number of hESCs in three wells was determined by
subtracting out the number of fibroblasts counted from the control
wells from the total number of cells. Cell counts were then plotted
versus the time of cells harvest and the doubling time was
calculated using Microsoft Excel software as described above.
Development of hESC Lines
Embryo culture and laser-assisted ICM
isolation. Thawing of embryos was performed using Embryo
Thaw Media (Irvine Scientific, Santa Ana, CA, USA). After
thawing, the embryos were cultured until day 3 of development in
Quinn’s AdvantageH Cleavage Medium and further to the
blastocyst stage in Quinn’s AdvantageH Blastocyst Medium, both
supplemented with 10% Quinn’s AdvantageH Serum Protein
Supplement (all from In-Vitro Fertilization Inc., Trumbull, CT,
USA). Blastocyst morphology was scored according to Stephen-
son, Braude and Ilic [54]. For assisted hatching, zona pellucidae
was perforated on day 3–4 by laser pulses (200 mW60.3 ms) from
a non-contact Zilos-tkTM infrared laser system (Hamilton Thorne
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40 um. Assisted hatching and ICM isolation was performed
according to our previously published methods [10].
In cases of collapse of blastocysts aged 5–6 days during assisted
hatching or ICM dissection, they were incubated overnight.
Another attempt of ICM isolation was then performed. In cases of
collapse of blastocysts aged 7 days, or in cases when the ICM was
non-detectable, whole blastocysts were plated on feeders for
further derivation of hESCs.
Research-grade Knockout medium
composition. Knockout Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 15% Knock-Out SR, 2 mM L-
glutamine, 1% nonessential amino acids, 50 U/ml penicillin,
50 mg/ml streptomycin (all from Invitrogen), supplemented with
4 ng/ml basic fibroblast growth factor (bFGF) (PeproTech Inc.,
Rocky Hill, NJ, USA).
Xeno-free GMP-grade hESCs culture system. For deri-
vation of hESCs, 1.5610
5 irradiated thawed WCB feeder cells
were plated in center-well tissue culture dishes (Falcon) pre-coated
with 0.1% 100 kDa rh-Gelatin (Fibrogen, San Francisco, CA,
USA) in Fibroblast Growth Medium. For weekly routine hESC
passaging, only 10
5 irradiated WCB feeder cells were plated. After
24 hours, the medium was replaced by hESC Medium comprised
of Cellgro-SCGM (CellGenix, Freiburg, Germany) supplemented
with 1% Human Serum Albumin (Irvine Scientific, Santa Ana,
CA, USA), 2 mM L-glutamine and 1% nonessential amino acids
(both from Hyclone), and with 8 ng/ml bFGF (R&D Systems,
Minneapolis, MN, USA). The hESC Medium was refreshed daily.
Feeders and hESCs were cultured at 37uCi n5 %C O 2.
Routine passaging of putative hESCs was performed by
mechanical dissection (Stem Cell Cutting Tool, Vitrolife, Sweden)
of the colonies into small clusters and plating on fresh feeders.
Cryopreservation of hESCs
Vitrification of hESCs. hESC clusters were vitrified using
Cryotips (FDA-approved as medical devices, Irvine Scientific) and
Irvine Scientific Vitrification Solutions (Vit-Kit Freeze Solutions,
Irvine Scientific) according to the manufacturer’s instructions with
modification of incubation times adapted from Reubinoff et al.,
2001 [45]. 5–6 small colony fragments were transferred to the
Equilibration Solution (ES) for 5 minutes, then to the Vitrification
Solution (VS) twice for 10 seconds and then to a final drop of VS
from which they were aspirated into the straw. The straws were
heat sealed and plunged into liquid nitrogen where they were
stored. Thawing was performed for 3 seconds in warmed sterile
water (37uC) followed by removal of hESC clusters from straws
and serial immersion in Irvine Scientific’s Vit Kit Thawing
Solutions (Irvine Scientific) according to the manufacturer’s
instructions.
Slow-cooling of hESCs. 8–10 hESC colony fragments were
transferred into 2.0 ml cryovials (Nunc) containing 1.0 ml
CryoStor 10 (Biolife Solutions, Bothell, WA USA) freezing
solution or 90% human serum (Lonza) and 10% DMSO (WAK-
Chemie). The vials were slow cooled in a freezing container (Mr.
Frosty, Nunc-Nalgene) to 280uC and then were stored in the
vapor phase of liquid nitrogen tanks (Custom Biogenic Systems).
Thawing was performed by warming at 37uC in a waterbath,
transferring into hESC culture medium, centrifuging at
1000 RPM for 3 minutes, and resuspending in hESC culture
medium.
Characterization of hESCs Lines
Analysis of HLA and STR fingerprinting. In order to
eliminate contamination by feeders, hESCs were cultured for a
minimum of three passages in a feeder-free culture system as
previously described [55] with slight modifications. STR analysis
was performed as described above for feeders. For HLA profiling,
the DNA was extracted using the MagNA Pure LC machine
(Roche Applies Sciences, Indianapolis, IN, USA). HLA- A, B,
DRB1, DQB1 loci at low resolution were typed using the Lipa
HLA kit (Murex Immunogenetics, Ghent, Belgium). High
resolution typing of the HLA- DRB1 and DQB1 alleles used the
PCR- Sequence Specific Primers method (PCR-SSP,Olerup kit,
Olerup, Stockholm, Sweden), according to the manufacturer’s
instructions. The HLA and STR analyses were done in the
Hadassah Tissue Typing Unit.
Alkaline phosphatase activity detection and
karyotyping. Vector Red Alkaline Phosphatase substrate kit I
(Vector Laboratories Inc., Burlingame, CA, US), Alkaline
Phosphatase Staining Kit II (Stemgent, Cambridge, MA, USA),
or AP Substrate Kit (Sigma) were used for detection of alkaline
phosphatase activity within intact colonies on feeders according to
the manufacturer’s instructions.
For karyotype analysis, hESC colonies that were expanded by
mechanical passaging on feeders, were incubated for 1 hour with
100 ng/ml Colcemid and then dissociated with trypsin (both from
Biological Industries, Beit Haemek, Israel). Incubation in hypo-
tonic solution and fixation was as described for the feeders. For the
primary reference banks, full analysis was performed on 30
metaphases spreads (20 for stocks and 2u cell bank), chromosome
counting on an additional 20 spreads (10 for stocks and 2u cell
bank), and 2 cells were photographed for each stock/bank.
Immunostaining. hESCs colonies that were cultured on
feeder layer for 4–6 days were fixed with 4% paraformaldehyde
for 20 min at RT. For immunostaining of intracellular markers,
cell membranes were permeabilized with 0.2% Triton X100
(Sigma), 5% normal goat serum (Beit Haemek) in PBS for 20 min.
The cells were incubated for 20–30 min at RT with the following
primary antibodies: anti-human Oct-3/4 antibody (1:50; Santa
Cruz Biotechnology Inc., USA), mouse monoclonal anti-human
TRA-1-60 (1:50), TRA-1-81 (1:50) and SSEA-4 (1:50) antibodies
(all from Chemicon International, Temecula, CA, USA) followed
by [fluorescein isothiocyanate (FITC)]-labeled goat anti-mouse
immunoglobulin (1:50, Dako). Rat monoclonal anti-human SSEA-
3 (1:50, Chemicon), followed by mouse anti-rat IgM conjugated to
R-PE, (1:20; Southern Biotechnology Associates Birmingham, Al,
USA) or Alexa Fluor- 488 labeled goat anti-rat IgM (1:100,
Invitrogen). Rabbit Polyclonal Anti KI-67 (1:100, Novo Castra
Laboratories), followed by FITC-conjugated Polyclonal Swine
Anti-Rabbit Immunoglobulins (1:10, Dako) was used. Mounting
medium containing DAPI (Vector) was used for nuclei counter-
staining and the specimens were visualized with a Nikon E600
fluorescent microscope.
FACS analysis. hESC colonies were dissociated with 0.05%
EDTA solution followed by gentle trituration to a single-cell
suspension. The hESCs were centrifuged and re-suspended in
FACS buffer. The cells were incubated with anti-TRA-1-60
(1:100), anti-TRA-1-81 (1:100), anti SSEA-4 (1:200), anti SSEA-1
(1:300; all from Chemicon) and anti SSEA-3 (1:100, Millipore) for
30 min at 4uC. As control, hESCs were stained with respective
isotype control antibodies (all from eBiosciences). Following
washing, primary antibodies were detected by incubating with
FITC-labeled goat anti-mouse Ig (1:100, Dako) and goat anti-rat
Ig (1:100, Invitrogen) for 30 min at 4uC. Following washing, the
cells were resuspended in FACS buffer supplemented with PI
(1:500 of 1 mg/ml solution, Sigma). FACS analysis was performed
using the FACSCalibur system (Becton Dickinson).
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described above for the characterization of feeders with slight
modifications. Irradiated cord feeder cells were plated in 16 center
well tissue culture dishes (10
5 cells/dish). Clusters of hESCs were
removed mechanically and equal numbers of clusters (numbers
ranged from 15–60) were plated per experiment in each of 12
center well tissue culture dishes (Falcon) leaving four dishes as
controls. HESCs together with feeder cells (in triplicates) were
harvested using Trypsin-EDTA (Invitrogen) and counted at four
time points. The number of cord feeder cells harvested at the same
time points from the control dishes was subtracted from the total
number of cells. The doubling time was calculated as above.
Analysis of pluripotency in vitro. Colonies of undifferen-
tiated hESCs were mechanically removed from the feeders and
cultured in suspension as embryoid bodies (EBs) or neurospheres.
For the development of EBs, the hESC free-floating clusters were
cultured 3 weeks in DMEM supplemented with 15–20% FCS,
2 mM L-glutamine, 1% nonessential amino acids, 50 U/ml
penicillin, 50 mg/ml streptomycin, 0.1 mM beta-mercaptoethanol
(all from Invitrogen). Neurospheres were developed as previously
described [56]. Briefly, the hESC clusters were cultured 3 weeks in
DMEM/F12 (1:1) supplemented with B-27 (1:50), 2 mM L-
Glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (all from
Invitrogen), 20 ng/ml bFGF and 500 ng/ml rm-Noggin (both
from Peprotech, London, UK).
After the 3 weeks of suspension culture, the EBs and the
neurospheres were partially dissociated by mild trypsin digestion
and plated on glass coverslips pretreated with 10 mg/ml poly-d-
lysine (Sigma) and 4 mg/ml laminin (Sigma), and cultured for an
additional 5–7 days in the respective culture media as above in the
absence of noggin and bFGF. They were fixed with 4%
paraformaldehyde and then stained with mouse monoclonal
anti-beta-tubulin isotype III (1:2000; Sigma), mouse monoclonal
anti-human desmin (1:50; Dako), or mouse monoclonal anti-
human muscle actin (1:50; Dako), and mouse monoclonal anti-
human sox-17 (1:50; R&D).
Polyclonal goat anti-mouse immunoglobulins conjugated to
FITC (1:50, Dako) or to Cy3 (1:1000, Jackson Laboratories) were
used to detect the primary antibodies. Mounting and visualization
was performed as above.
Analysis of pluripotency in vivo. Subject to an approval of
the Institutional Ethical Committee for Care and Use of Animals,
4–5 week old NOD SCID mice (Harlan, Jerusalem, Israel) were
subcutaneously inoculated utilizing a 25 G needle with 100–200
small clusters of approximately 500 cells of undifferentiated hESCs
in each cluster, which had been mechanically removed from the
feeders. The hESCs were injected with 1610
6 irradiated cord
fibroblasts cells, in a total volume of 60 ul, together with an equal
volume of Matrigel (Basement membrane matrix, Becton Dick-
enson Biosciences). Maximum teratoma size permitted was
15 mm. 8–12 weeks later, the resulting tumors were removed,
fixed in neutral buffered 4% formalin, embedded in paraffin, and
examined histologically after hematoxylin and eosin staining.
Gene expression. RNA preparation: Total RNA was prepared
from Trizol (Invitrogen) lysates of hESCs colonies, 5–6 days after
passage, and embryoid bodies (EBs as above), after 3–4 weeks of
differentiation. DNA was removed with DNA-free (Ambion,
Austin, TX, USA). cDNA synthesis was carried out using Moloney
murine leukemia virus reverse transcriptase (MMLV RT,
Promega, Madison, WI, USA) and random hexamers (Promega),
according to the manufacturer’s instructions (Promega).
Real Time PCR: For quantitative gene expression analysis Low
density TaqMan array: Human stem Cell Panel, Applied
Biosystems Part Number 4385344 was used with Taqman Gene
Expression Master Mix (Applied Biosystems, Foster City, CA,
USA). ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems) was used.
Gene expression was analyzed using the DataAssist Software
v2.0 (Applied Biosystems).
Safety Testing
Feeders and hESCs were outsourced for testing at Bioreliance
(Glasgow, UK) and the Hadassah Virology and Hepatology
Laboratories.
Statistical Analysis
Data are presented as mean 6S.E.M. The significance of
multiple comparisons was determined using one way analysis of
variance (ANOVA) with Tukey-Kramer multiple comparisons
test.
Supporting Information
Figure S1 Characterization of the primary cell bank of
clinical grade HADC102 hESCs. The hESCs colonies were
comprised of small tightly packed cells with a high nuclear to
cytoplasmic ratio. Clear distinguishable borders were observed
between the colonies and cord feeder cells, (A; phase-contrast
image). The cells expressed alkaline phosphatase (B; AP,
fluorescence image). Indirect immunofluorescence staining showed
that the hESCs were immunoreactive with anti-Oct-4 (C; D,
nuclear 4’,6-Diamidino-2-phenylindole (DAPI) counter staining),
TRA-1-60 (E), TRA-1-81 (F), SSEA-3 (G), and SSEA-4 (H). FACS
analysis showed that the majority of cells expressed markers of
pluripotency TRA-1-60 (I), TRA-1-81 (J) and SSEA-3 (K) (Data
from a representative experiment). The hESCs had normal
karyotype (46, XY; L) and could differentiate in vitro in vivo into
cells representing the three embryonic germ layers (M-R).
Immunofluorescence staining showing in vitro differentiated cells
expressing beta-tubulin III (ectoderm, M), muscle actin (meso-
derm, N) and sox-17 (endoderm, O). Hematoxylin-eosin stained
histological sections of teratoma tumors showing neural rosettes
(ectoderm, P), cartilage (mesoderm, Q) and columnar glandular
epithelium with goblet cells (endoderm, R). Scale bar represent
20 um for (Q and R), 50 um for (B, C, D, N and O), 100 um for
(A, M and P) and 200 um for (E -H).
(TIF)
Figure S2 Characterization of the primary cell bank of
clinical grade HADC106 hESCs The hESCs colonies were
comprised of small tightly packed cells with a high nuclear to
cytoplasmic ratio. Clear distinguishable borders were observed
between the colonies and cord feeder cells, (A; phase-contrast
image). The cells expressed alkaline phosphatase (B; AP,
fluorescence image). Indirect immunofluorescence staining showed
that the hESCs were immunoreactive with anti-Oct-4 (C; D,
nuclear 4’,6-Diamidino-2-phenylindole (DAPI) counter staining),
TRA-1-60 (E), TRA-1-81 (F), SSEA-3 (G), and SSEA-4 (H). FACS
analysis showed that the majority of cells expressed markers of
pluripotency TRA-1-60 (I), TRA-1-81 (J) and SSEA-3 (K) (Data
from a representative experiment). The hESCs had normal
karyotype (46, XY; L) and could differentiate in vitro in vivo into
cells representing the three embryonic germ layers (M–R).
Immunofluorescence staining showing in vitro differentiated cells
expressing beta-tubulin III (ectoderm, M), muscle actin (meso-
derm, N) and sox-17 (endoderm, O). Hematoxylin-eosin stained
histological sections of teratoma tumors showing neural rosettes
(ectoderm, P), cartilage (mesoderm, Q) and villi structures with
columnar glandular epithelium and goblet cells (endoderm, R).
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(TIF)
Figure S3 Characterization of the secondary cell bank of
clinical grade HADC100 hESCs. The hESCs colonies were
comprised of small tightly packed cells with a high nuclear to
cytoplasmic ratio. Clear distinguishable borders were observed
between the colonies and cord feeder cells, (A; phase-contrast
image). The cells expressed alkaline phosphatase (B; AP,
fluorescence image). Indirect immunofluorescence staining showed
that the hESCs were immunoreactive with anti-Oct-4 (C; D,
nuclear 4’,6-Diamidino-2-phenylindole (DAPI) counter staining),
TRA-1-60 (E), TRA-1-81 (F), SSEA-3 (G), and SSEA-4 (H). FACS
analysis showed that the majority of cells expressed markers of
pluripotency TRA-1-60 (I), TRA-1-81 (J) and SSEA-3 (K) (Data
from a representative experiment). The hESCs had normal
karyotype (46, XY; L) and could differentiate in vitro and in vivo
into cells representing the three embryonic germ layers (M–R).
Immunofluorescence staining showing in vitro differentiated cells
expressing b-tubulin III (ectoderm, M), muscle actin (mesoderm,
N) and sox-17 (endoderm, O). Hematoxylin-eosin stained
histological sections of teratoma tumors showing neural rosettes
(ectoderm, P), cartilage (mesoderm, Q) and columnar glandular
epithelium with goblet cells (endoderm, R). Scale bar represent
50 um for (A, B, N, O, P, Q and R), 100 um for (C, D and M) and
200 um for (E–H).
(TIF)
Figure S4 The majority of hESCs are in an active cell
cycle. Indirect immunofluorescence analysis shows that the
majority of hESCs in each of the cell banks are immunoreactive
with anti-KI67. (Green: Quantitative analysis of the percentage of
KI67+ cells within 200 cells in each of three random fields appears
in brackets). Low magnification images and corresponding nuclei
DAPI counterstaining are presented in the left two columns, while
higher magnification in the right two columns.
(TIF)
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